LZAGF

PINK Lonza Group AG
Oct 2, 2026 · 2:37 AM ET EOD Market Closed

$682.21 ↑ +0.00 (+0.00%) Trading Up from the previous close of $682.21, $24.44 below the day’s high of $706.65

YTD change
+0.26%
vs 20-day SMA
-0.13%
vs 200-day SMA
+1.84%

Price ranges

Previous day
$674.05 $718.55
open $674.95 close $694.21
+$19.26 (+2.85%)
Today
$663.27 $706.65
open $663.85 now $682.21
+$18.36 (+2.77%)
Past week
$657.50 $727.46
from $674.45 now $682.21
+$7.76 (+1.15%)
Past month
$629.54 $745.74
from $730.30 now $682.21
-$48.09 (-6.58%)
This year
$565.14 $753.32
from $680.45 now $682.21
+$1.76 (+0.26%)

Price & Performance

+38.31 (+5.95%) / 6M

$586.85$642.93$699.02$755.10Apr 1Jul 2Oct 1

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral
  • The stock is 20.0% away from all-time highs of $852.25
  • LZAGF is up 0% since the beginning of the year
  • LZAGF is down 0% over the past 12 months
  • LZAGF is down 7% over the past 1 month
  • 0% of all LZAGF investors are betting against LZAGF

LZAGF reads neutral: price sits above one of the two key moving averages, the 12-month move is -0.1%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes
EPS $0.175996
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Beta 0.80

Balance sheet & scale

Income$1.3M
Revenue$8.0B
Cash$603.7M
Debt$5.2M
Income / Debt 0.26×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangePINK
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $47.6B

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

Competitor comparison

TickerCompany PriceChange
LLY Eli Lilly and Company $1,149.85 -0.62%
JNJ Johnson & Johnson $258.66 -2.30%
ABBV AbbVie, Inc. $259.93 -0.63%
MRK Merck & Co., Inc. $143.81 -1.03%
RHHVF Roche Holding Ltd $442.60 +6.66%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.